Free Newsletter
Sanofi to invest $6B in vaccine production
The growing wealth seen in developing nations is spurring a big increase in the worldwide demand for vaccines, and Sanofi-Aventis says it will invest more than $6 billion over the next eight years in order to meet the projected demand. Wayne Pisano, who heads Sanofi's vaccine division, estimated that total vaccine sales for the company will double to $34 billion by 2016. That growth will come in countries like India and China, where larger incomes are driving the demand for new flu and pediatric vaccines.
For years the low cost of vaccines made the sector a low-key player in biopharma. Now the relatively low cost of a vaccination and the significant health benefits that can be achieved from a major vaccination program have prompted more countries to step up their work in the field, making vaccines one of the hottest sectors in the industry.
"We have a number of diseases where there is not enough capacity today, where there is demand and there's not enough supply," Pisano told reporters.
- read the Wall Street Journal story
Related Articles:
Sanofi files new vaccine tech
Booming vaccine market swells Sanofi's revenue
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




